ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Right, left and centre
An article featuring expert commentary from ICON's Gretchen Goller on the importance of including patients at every stage of drug development.
Innovation in oncology drug development: A focus on patient benefits
An article by ICON's Dr. Brian Huber that examines how innovation, from the development of targeted therapies to a revolution in clinical trial designs, puts an emphasis on patient centricity.
Decentralised and hybrid trials – the patient’s voice
A thought leadership article by ICON's Gretchen Goller on getting the patient perspective on clinical trial participation.
A pathway to recovery
An opinion article from ICON's Chief Medical Officer, Kristen Buck on the role of Chief Medical Officers.
Treatment options for Clostridioides difficile
This thought leadership article explores the increase in antimicrobial-resistant infections such as C diff due to the high volume of patients being treated in hosipitals for COVID-19.
An outsourced model for pharmacovigilance at an affiliate level
An article authored by ICON's Barry Rice and Sharlene Ahmed, which focuses on improving oversight and reducing the risk of non-compliance.
A golden opportunity… but not a silver bullet
This spotlight feature authored by ICON's Barry Balfe examines how pharmaceutical companies are increasing their functional service partnership expenditure at a rapid rate, and the key considerations in selecting and executing the FSP model which are being overlooked.
Decentralised trials – aided by tech – could boost clinical research
An article which considers how bringing clinical trials to patients – rather than the reverse – could be the key to improving recruitment into studies and making them faster, cheaper and more likely to succeed.
Estimands in practice: Bridging the gap between study objectives and statistical analysis
An article by ICON experts Alan Phillips and Tim Clark which examines the progress that has been made since 2018 when implementing the estimand framework within clinical research.
Adapting for the future of oncology
ICON experts Andreas Dreps and Martin Lachs share their thoughts on the future of cancer research and the importance of staying adaptive in PharmaPhorum's 'Future of Oncology 2020' magazine.